Neuraxpharm, a leading European specialty pharmaceutical company, today announces its “Change for Health” campaign that aims to increase the acceptance of medical cannabis and provide...
Neuraxpharm Group (“Neuraxpharm”) today announced that it has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases...
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through...
Dr. Dadi Segal, CEO of Panaxia Global, said, “After obtaining a marketing permit in Germany, which was a very significant milestone for us, we are proud to...
Panaxia Global, the controlling owner of Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), Israel’s largest manufacturer of medical cannabis products, and its partner, Neuraxpharm, Europe’s leading pharmaceutical company specialized in...